ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,724.30
-0.33%
S&P ASX All Technology
3,092.70
-1.13%
Brent Oil
82.275
0.00%
US Dollar vs AUD
1.51378
0.08%
Bitcoin
66,255.70
0.38%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Stoke Therapeutics Inc (STOK)

  7. Stoke Therapeutics Inc (STOK) News

STOK

Stoke Therapeutics (STOK)

Stoke Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:STOK
DateTimeSourceHeadlineSymbolCompany
14/06/202406:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:STOKStoke Therapeutics Inc
08/06/202406:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
08/06/202406:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
08/06/202406:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
08/06/202406:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
08/06/202406:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
07/06/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
06/06/202406:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
04/06/202406:30Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in JuneNASDAQ:STOKStoke Therapeutics Inc
23/05/202406:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
23/05/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
21/05/202406:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
21/05/202406:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
18/05/202406:30Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:STOKStoke Therapeutics Inc
18/05/202406:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
18/05/202406:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
07/05/202406:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STOKStoke Therapeutics Inc
06/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
06/05/202421:00Business WireStoke Therapeutics Reports First Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
29/04/202422:00Business WireStoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerNASDAQ:STOKStoke Therapeutics Inc
17/04/202422:00Business WireStoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerNASDAQ:STOKStoke Therapeutics Inc
05/04/202407:30Business WireStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
28/03/202414:40Business WireStoke Therapeutics Announces Pricing of Upsized $125 Million Public OfferingNASDAQ:STOKStoke Therapeutics Inc
27/03/202407:07Business WireStoke Therapeutics Announces Proposed Public OfferingNASDAQ:STOKStoke Therapeutics Inc
26/03/202407:01Business WireStoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:STOKStoke Therapeutics Inc
26/03/202407:01Business WireStoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
06/03/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
02/03/202408:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
27/02/202402:38Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:STOKStoke Therapeutics Inc
27/02/202402:36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:STOKStoke Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:STOK

Your Recent History

ASX
XAO
Australian SE All Ordina...
NASDAQ
TSLA
Tesla
ASX
XTO
S&P ASX 100
ASX
ORG
Origin Energy
SPI
SP500
S&P 500
ASX
MQG
Macquarie
FX
AUDJPY
AUD vs Yen
NASDAQ
MSFT
Microsoft
NYSE
VZ
Verizon Communications
ASX
RIO
Rio Tinto
FX
EURAUD
Euro vs AUD
ASX
TLS
Telstra
FX
AUDCAD
AUD vs CAD
ASX
SUN
Suncorp
NYSE
MRK
Merck
ASX
CSL
CSL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved